Brain endocannabinoid system is proposed to play a role in the pathogenesis of affective disorders. In the present study, we analyzed the functionality of the cannabinoid receptor type 1 (CB 1 receptor) at different transduction levels in prefrontal cortex (PFC) of depressed suicide victims. We examined stimulation of coupling to Gα o , but not to Gα i1 , Gα i2 , Gα i3 , Gα z subunits, in the PFC from AD-free MD suicides. These results suggest that increased CB 1 receptor functionality at the Gα i/o protein level in the PFC of MD subjects is due to enhanced coupling to Gα o proteins and might be modulated by AD intake. These data provide new insights into the role of endocannabinoid neurotransmission in the pathobiology of MD and suggest its regulation by ADs.
Introduction
Major depression (MD) is a chronic, recurrent and prevalent disorder with major impacts in quality of life and cost of health care. Despite decades of intense research, there is a relative lack of knowledge regarding the aetiology of depression. In this sense, the majority of research in animal models and postmortem human brain suggests that alterations in the number and/or functionality of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) receptors, reflecting a deficit in these neurotransmission systems, are involved in the pathogenesis of MD [1] [2] [3] . Indeed, depression is commonly treated with antidepressant compounds (ADs) that increase the synaptic content of 5-HT and/or NE [4] . Nevertheless, the clinical improvement associated to ADs intake results evident only after several weeks of treatment, suggesting that the acute enhancement of monoaminergic neurotransmission is not responsible for the therapeutic efficacy of these drugs [5] . More importantly, less than 50% of the patients with depression experience complete remission following antidepressant treatment [4] . Current research towards the development of more effective ADs is aimed at improving our understanding of the mechanisms that contribute to the pathophysiology of depression, and to the efficacy of nowadays available antidepressant medications.
Converging evidence suggest that targeting brain endocannabinoid system may be a useful strategy for the development of new antidepressant medications [4, 6] . Cannabinoid CB 1 receptor is the main subtype in the central nervous system, and its transduction mechanisms include the inhibition of adenylyl cyclase (AC) as well as the modulation of ionic currents via G i/o proteins [7] , and the activation of the mitogen-activated protein kinase (MAPK) pathway [8] . CB 1 receptors are expressed in high levels in brain areas relevant to depression, such us the prefrontal cortex (PFC) or the hippocampus [9] . Thus, the pharmacological or genetic blockade of CB 1 cannabinoid receptors in animal studies result in behavioral responses that resemble human depressive symptoms [10, 11] . On contrast, other studies indicate that CB 1 receptor mRNA, protein expression and/or signaling in the PFC are upregulated in animal models of the disease [12] [13] [14] [15] . Similar discrepancies have been described in association to antidepressant treatment. Thus, the acute CB 1 receptor activation produces antidepressant responses and enhances the effects of ADs in rodents [12, 16] , although antidepressant effects resulting from CB 1 receptor blockade have also been reported [17] . Finally, a number of studies have shown that chronic administration of ADs modulates the activity of brain endocannabinoid system [13, 14, 18, 19] . All these data support a role of the endocannabinoid system in MD.
Despite these accumulating data from research using animal models, limited information that supports a role for CB 1 receptors in depression is nowadays available from human studies [20] . In this sense, variation of the gene coding for the CB 1 receptor has been shown to influence both the susceptibility to MD and the response to AD treatment [20] [21] [22] [23] [24] . With regard to postmortem studies, we [25] and others [26, 27] have demonstrated increased CB 1 receptor mediated activation of G i/o proteins in the PFC of depressed suicide victims. However, the mechanisms underlying this observed upregulation of CB 1 receptor signaling in MD subjects, its possible modulation by ADs, and the resulting consequences downstream G i/o proteins, have not been investigated in detail. The aim of this study was to examine specific molecular mechanisms linked to the activation of CB 1 receptors in MD. Specifically, we addressed CB 1 receptor-mediated activation of different Gα protein subunits and regulation of adenylyl cyclase in the postmortem prefrontal cortex of subjects with major depressive disorder. The study was designed to assess the possible influence of antidepressant treatment on these parameters. These data would provide new insights to the participation of CB 1 receptors in the pathophysiology of depression, and strengthen the idea that targeting brain endocannabinoid system may be a useful strategy for the treatment of this psychiatric illness.
Materials and methods

Subject selection and toxicological screening
Human brain PFC samples (Brodmann's area 9) were obtained at autopsies performed in the Basque Institute of Legal Medicine, Bilbao, and in the Service of Pathologic Anatomy of the "Marqués de Valdecilla" Universitary Hospital, Santander, Spain. Brain tissue collection was performed in accordance with the approved protocols of the Basque Institute of Legal Medicine and the "Marqués de Valdecilla" University Hospital for postmortem human studies. All the deaths were subjected to retrospective careful search for previous medical diagnosis and treatment using examiner's information and records of hospitals and mental health centers. This searching was blind to the biochemical findings. After searching for antemortem information, the brains from suicide victims who fulfilled the DSM-IV criteria of the American Psychiatric Association [28] for MD were selected. Serum samples from all the MD and control subjects included in the study were assayed for the presence of antidepressant, antipsychotic and anxiolytic drugs, as well as for psychotropic drugs (including delta-9-tetrahidrocannabinol, Δ 9 -THC) and alcohol. The laboratory analyses were performed at the National Institute of Toxicology, Madrid, Spain. Control subjects with a positive toxicological test for psychotropic drugs were excluded from the study. Toxicological screening was positive for antidepressants in six suicide victims (cases 2, 4, 7, 8, 9 and 10 from Table 1 ). These cases will be referred as "antidepressant-treated subjects" (AD-treated). The demographic characteristics, prescribed treatments and laboratory screening results of the MD and control subjects included in the study are detailed in Table 1 . Due to tissue availability limitations, all experimental procedures could not be carried out in the same cohorts of MD and control cases. Nevertheless, the MD PFC samples included in each experimental technique were always carefully matched in terms of gender, age at death and postmortem delay (PM) with control samples obtained from subjects without evidence of neurological or psychiatric disorder and who died by a non-suicide mechanism. All the assays were carried out in a parallel design, so that in a given experiment, PFC samples from a MD brain were processed and incubated in parallel with the ones obtained from a matched control.
Agonist-stimulation of [ 35 S]GTPγS binding
PFC samples were homogenized (1:20 w/v) in ice-cold buffer (50 mM Tris-HCl, 3 mM MgCl 2 , 1 mM ethylene glycol tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT) and 250 mM sucrose; pH, 7.4) using a Teflon tissue grinder (10 s, 800 rpm). The homogenates were centrifuged (1000g, 15 min, 4°C) and the resulting supernatants were then centrifuged at 40,000g for 15 min (4°C). The obtained pellets were resuspended in the same buffer and centrifuged again (50,000g, 15 min, 4°C). Pellets were again resuspended and membrane aliquots (50 μg protein/ml in the assay) were incubated for 120 min at 30°C in assay buffer (50 mM Tris-HCl, 3 mM MgCl 2 , 1 mM EGTA, 100 mM NaCl, 100 μM guanosine diphosphate (GDP), 0.2 mM DTT, 0.5% bovine serum albumin (BSA); pH, 7.4) containing 0.05 nM [ Reserche, Montpellier, France). Basal binding was determined in the absence of agonist and non-specific binding was measured by coincubation with 10 μM GTPγS. The experiments were terminated by rapid filtration under vacuum (Cell Harvester M-12R, Brandel, Gaithersburg, MD, USA) through GF/C glass fiber filters, followed by three washes in ice-cold buffer (50 mM Tris-HCl, 1 mg/ml BSA; pH, 7.4). Bound radioactivity was determined using a Beckman LS6000 liquid scintillation counter (Beckman Instruments Inc., Fullerton, CA, USA), after overnight extraction in 5 ml Ecolite scintillation fluid (MP Biomedicals, LLC, Solon, OH, USA). All assays were performed in triplicate Sigmacote (Sigma-Aldrich Quimica SL, Madrid, Spain)-treated borosilicate tubes, and the results were confirmed in two independent experiments.
[ 3 H]CP55,940 saturation binding assay
Frozen PFC samples were homogenized (1:20 w/v) in ice-cold buffer (50 mM Tris-HCl, 1 mM ethylenediaminetetraacetic acid (EDTA) and 250 mM sucrose; pH, 7.4) using a motor driven Teflon and glass tissue grinder (10 s, 800 rpm). Homogenates were first centrifuged (1000g, 10 min, 4°C) and the supernatants were centrifuged (50000g, 15 min, 4°C). The obtained pellets were resuspended in assay buffer (50 mM Tris-HCl, 1 mM EDTA, 3 mM MgCl 2 ; pH, 7.4), incubated for 15 min at 37°C and centrifuged again (50000g, 15 min, 4°C). The pellets were resuspended (50 μg protein/ml in the assay) and incubated for 60 min at 37°C in assay buffer with the cannabinoid agonist [ 
Agonist-inhibition of adenylyl cyclase activity
PFC samples were homogenized (1:70 w/v) in ice-cold buffer (20 mM Tris-HCl, 1 mM EGTA, 5 mM EDTA, 1 mM DTT, 25 μM leupeptine and 300 mM sucrose; pH, 7.4) using a Teflon tissue grinder (10 s, 800 rpm) and centrifuged (1500g, 5 min, 4°C), with the resulting supernatants centrifuged again (13,000g, 15 min, 4°C). The obtained pellets were resuspended (150 μg protein/ml) in ice-cold assay buffer (80 mM Tris-HCl, 0.2 mM EGTA, 1 mM EDTA, 2 mM MgCl 2 , 100 mM NaCl, 60 mM sucrose, 1 mM DTT, 10 μM guanosine triphosphate (GTP), 0.5 mg/ml BSA, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 5 mM phosphocreatine, 50 U/ml creatine phosphokinase, 5 U/ml myokinase and 5 μM forskolin; pH, 7.4), and incubated for 5 min at 37°C in the presence of WIN55,212-2 (10 nM-100 μM). The specificity of the cannabinoid agonist was verified by incubation of WIN55,212-2 (10 μM) with the selective CB 1 receptor antagonist SR141716A (10 μM). The enzymatic reaction was started by addition of ATP to a final concentration of 200 μM. The mixture was then incubated for 10 min at 37°C, and the reaction was rapidly terminated by 5 min incubation at 100°C. The samples were centrifuged (5 min, 13,000g) and cyclic AMP (cAMP) concentration was determined in the supernatants using the Membrane suspensions were then solubilized on ice with 1% Igepal® (Sigma-Aldrich Quimica SL, Madrid, Spain), 0.5% sodium deoxycholate, 0.1% SDS, 2.5 mM CHAPS, 0.1 mM phenylmethylsulfonylfluoride (PMSF), 0.01 M aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µl/ml antipain, 10 µg/ml chymostatin (Sigma-Aldrich Quimica SL, Madrid, Spain) for 30 min. Solubilized membranes were incubated for 3 h at room temperature with 15 μl of specific rabbit anti-Gα i2 , anti-Gα i3 , anti-Gα z , anti-Gα o antibodies (Santa Cruz Biotechnology Inc., Dallas, TX, USA) and immobilized to superparamagnetic Dynabeads® Protein A (Thermo Fisher Scientific Baltics, UAB, Vilnius, Lithuania) overnight at 4°C. After three washes with 1 ml de phosphate buffered saline (PBS) the beads were pelleted and the entrapped radioactivity was counted in 4 ml of Ecolite scintillation cocktail. Antibody specificity was confirmed in our experimental conditions by Western blot as reported previously [29] .
Protein content determination
Membrane protein content was determined with the Bio-Rad Protein Assay Kit (Bio-Rad, Munich, Germany), using γ-globulin as standard.
Data analysis
The effect of each concentration of cannabinoid agonist was expressed as percentage of stimulation (% = (agonist effect × 100)/ (basal activity-100)) in [ The statistical analysis was performed in two phases. Initially, and in order to confirm that the MD and control PFC samples included in each experimental procedure were properly matched in terms of age and PM, these demographic parameters were compared between both groups of cases by means of unpaired Student's t-tests [30, 31] (Table 2 ). In addition, MD and control groups assayed in the four different techniques were comparable in terms of age and PM, as evidenced by oneway ANOVA analysis performed for each variable (age or PM) in both MD and control groups.
Secondly, data obtained in each experimental technique for MD and matched control groups were compared using two-sided paired Student's t-tests [31] [32] [33] . Additionally, results from MD subjects with negative or positive toxicology for ADs at the time of death (AD-free and AD-treated, respectively) and their respective control subgroups were analyzed using two-way ANOVA (disease and treatment) followed by Bonferroni post-hoc test. The statistical analysis test used for each experimental set are indicated in the results section and figure and table legends. Differences were taken as statistically significant when p < 0.05. Data are presented as mean ± SEM.
Results
Demographic characteristics of the samples
Because the MD and control subjects were matched in terms of gender, age at death and PM (Table 1) , we detected no differences when comparing these parameters between the cases included in each experimental technique (Table 2 ). Between 8 and 10 MD subjects out of a total number of twelve, and their matched controls, were included in each of the biochemical assays performed (receptor binding, [ (Fig. 1A) (Fig. 1B) . By contrast, we did not detect differences in the %E max of the cannabinoid agonist when comparing AD-treated MD subjects to their matched controls (309.7 ± 33.5 AD-treated-MD vs 282 ± 8.7% control) (Fig. 1B) . Similarly, two-way ANOVA detected no differences between experimental groups concerning basal [ 35 S]GTPγS binding or the potency of WIN55,212-2 binding in these assays.
CB 1 receptor expression and agonist inhibition of adenylyl cyclase activity
Previous data have suggested that the upregulation of CB 1 receptorstimulated [ 35 S]GTPγS binding in the PFC of depressed suicide victims reflects an increased number of CB 1 proteins [26] . This possibility was assessed in our spanish cohort of MD suicide cases by means of Group values are mean ± SEM and p values correspond to non-paired Student's t-tests. 1 Age at death (years). 2 Postmortem delay (hours). We next tested whether the observed upregulation of CB 1 coupling to Gα i/o in the PFC of MD suicide victims could be detected at the adenylyl cyclase signal transduction level. Similar basal adenylyl cyclase activity and forskolin effect values were measured in PFC from the Fig. 1. CB 1 receptor-mediated (D) Comparison of the effect of WIN55,212-2 to activate Gα subunits in MD cases with relation to AD intake. The increased activation of Gα proteins by WIN55,212-2 in depressed subjects is due to a selective enhancement in the ability of the cannabinoid agonist to stimulate Gα o subunits in AD-free cases (n = 5 AD-free + 5 AD-treated MD and control cases; # p < 0.05, two-way ANOVA followed by Bonferroni post-hoc test vs control cases). Control AD-: matching control of MD AD-free subjects; control AD+: matching control of MD AD-treated subjects. MD and control brains ( Table 3) . Comparison of the maximal inhibitory effect (%I max ) and the potency (pEC 50 ) of the cannabinoid agonist WIN55,212-2 in cAMP assays using paired Student's t-test yielded no difference between depressed suicide victims and their matched control cases (Table 3) . Similarly, a two-way ANOVA analysis revealed no differences between AD-free and AD-treated MD cases and their respective control subgroups regarding basal and forskolin-stimulated adenylyl cyclase activity, %I max and pEC 50 of WIN55,212-2 values in cAMP experiments.
3.4. CB 1 receptor-mediated immunoprecipitation of [
S]GTPγS labeled Gα subunits
In the absence of changes in CB 1 receptor density, the lack of parallelism between the enhanced activation of Gα i/o proteins and the unaltered inhibition of AC activity by WIN55,212-2 may suggest altered receptor coupling ability to specific Gα subunits in the PFC of depressed suicide victims. In order to test this hypothesis, we performed immunoprecipitation of WIN55,212-2-stimulated [ (Fig. 1C) . The coupling efficiency of CB 1 receptors at Gα proteins, as determined by the ability of the cannabinoid agonist WIN55,212-2 to induce the activation of specific protein subunits, in the PFC of control subjects was: Gα i3 (235% ± 35%) > Gα i2 (174% ± 17%) > Gα o (153% ± 7%) > Gα i1 (123% ± 9%) > Gα z (108% ± 6%) (Fig. 1C) . We detected a non-significant increase in the activation of Gα o subunits by WIN55,212-2 in the MD group (197 ± 24% MD vs 153 ± 7% control, p = 0.06). However, the coupling to Gα i1 (129 ± 17% MD vs 123 ± 9% control, p = 0.38), Gα i2 (158 ± 19% MD vs 174 ± 17% control, p = 0.33), Gα i3 (235 ± 35% MD vs 214 ± 22 control%, p = 0.29) or Gα z (115 ± 12% MD vs 108 ± 6% control, p = 0.31) was similar between MD and control subjects (paired Student's t-tests) (Fig. 1C) . A two-way ANOVA analysis of the total G proteins activated by WIN55,212-2 in AD-free and AD-treated subgroups showed a significant effect of the disease [F(1,16) = 4.807, p < 0.05] and no significant changes for treatment and interaction (Fig. 1D) . AD-free depressed suicide subjects showed a higher total Gα protein binding compared to their matched controls (279 ± 15% ADfree MD vs 181 ± 29% control; p < 0.05, Bonferroni post-hoc test) (Fig. 1D) . Moreover, a two-way ANOVA analysis of the Gα o protein subunits showed a significant effect of the disease [F(1,16) = 4.549, p < 0.05], the treatment [F(1,16) = 6.042, p < 0.05], and the interaction disease x treatment [F(1,16) = 4.957, p < 0.05]. AD-free depressed suicide victims presented higher Gα o protein binding when compared to their matched controls (245 ± 33% AD-free MD vs 155 ± 14% control; p < 0.05, Bonferroni post-hoc test) (Fig. 1D) . This increase was not observed when comparing the MD AD-treated group with their respective control cases (Fig. 1D) . By contrast, two-way ANOVA revealed no differences in the efficacy of WIN55,212-2 to activate Gα i1 , Gα i2 , Gα i3 and Gα z between AD-free or AD-treated depressed subjects and their respective control cases (Fig. 1D ).
Discussion
Increasing our current knowledge on the neurobiological basis of MD is a necessary step towards the development of more efficacious antidepressant medications. During the last decade, evidence has accumulated from studies in animal models that consistently suggest the participation of the endocannabinoid system in the pathophysiology of depression and in the long-term effects of ADs [6] . In this regard, the biological relevance of CB 1 receptors in human depression is highlighted by reports of psychiatric adverse reactions, including depression and suicidal behaviour, associated to the use of the CB 1 receptor antagonist rimonabant in clinical trials for the prevention of cardiovascular risk [34, 35] .
The results of the present study show increased CB 1 receptormediated stimulation of [ 35 S]GTPγS binding in the PFC of depressed suicides compared to matched controls, in agreement with previous reports [26, 27] . Nevertheless, our data also suggest that this augmented activation of G i/o proteins by the cannabinoid agonist WIN55,212-2 does not result from increased CB 1 receptor density in the PFC of MD cases. Consistently, enhanced CB 1 receptor-mediated inhibition of AC, which is likely to be expected from an elevated density of the receptor protein, was not detected in the PFC of the MD subjects included in the present study. Together with the data of Hungund et al. [26] and Choi et al. [27] , our data strengthen the idea that enhanced CB 1 receptor signaling at the G i/o protein level in the PFC is a consistent finding in MD, although the underlying mechanisms may differ, probably due to the heterogeneity of this disease. Further evidence of the complex role of endocannabinoid signalling in MD comes from results showing association of lower CB 1 receptor density in cannabis abusers [36] to both higher incidence [37] and lower risk [38] of suffering MD.
Stimulation of CB 1 receptors by WIN55,212-2 resulted in the activation of at least five different Gα i/o protein subunits in human PFC, in agreement with previous studies [39] . These results differ from own observations in rodent PFC, where we detected no significant coupling to Gα i1 using the same anti-Gα subunit antibodies [19] while Gα z proteins are more significantly activated [40] . Regarding MD cases, agonist-stimulated immunoprecipitation assays revealed augmented CB 1 [42, 43] . It is also noteworthy that, in contrast to the observed upregulation of CB 1 receptor coupling to Gα o proteins, similar stimulation of Gα i1 , Gα i2 , Gα i3 and Gα z proteins was detected when comparing our cohort of MD subjects versus matched controls. Both CB 1 receptor coupling to the inhibition of AC and to the regulation of different K + and Ca 2+ conductances in neural tissue have been shown to occur through pertussis toxin-sensitive Gα i/o proteins [7] , although the specific Gα subunits involved in each response have not been characterized in detail. Proteins of the Gα i and Gα z subfamilies are responsible for the inhibitory regulation of adenylyl cyclase activity by G protein-coupled receptors, whereas the Gα o subtypes are more consistently involved in the modulation of ion channel function [44] [45] [46] . Moreover, Gα o protein subtype has no inhibitory effect on adenylyl cyclase activity [44, 47] . In this scenario, the observed profile of CB 1 receptor coupling to Gα subunits in the PFC of depressed suicides is consistent with the reported absence of changes at the AC transduction level, and may point to an altered regulation of ion channel function by neural CB 1 receptors in MD. A possible explanation for the increased activation of Gα o subunits by CB 1 receptors reported here could be the existence of an enhanced expression of these G proteins in the brain of depressed patients [2] . Although the limited availability of tissue did not allow us to perform immunoblotting assays for these proteins in our samples, the majority of postmortem studies indicate unchanged levels of Gα i1/2 and Gα o proteins in the brain of suicide victims [3, [48] [49] [50] . Consistently, previous observations suggest normal levels of G i/o protein activation by other neurotransmitter receptors in the PFC of suicide victims with mood disorders [3] . These evidences suggest that the functional upregulation of CB 1 receptors reported here is neither a common feature for other receptor systems coupled to Gα o proteins, nor related to enhanced expression of Gα o subunits in the PFC of subjects with MD.
An interesting finding of the present study is that both the augmented stimulation of [ 35 S]GTPγS binding and the increased activation of Gα o subunits by CB 1 receptors were selectively found in the PFC of AD-free depressed suicides, being absent when comparing AD-treated depressed suicides with their matched controls. This fact suggest that the enhanced signaling of CB 1 receptors at the Gα o protein level in the brain of MD subjects is related to the pathobiology of depression, and not to the intake of antidepressant medication, as previously suggested in the study by Hungund et al. [26] . In second place, these results support the idea that antidepressant medications may modulate endocannabinoid neurotransmission in the human brain, as suggested from animal studies [13, 14] . In this regard, repeated administration of ADs to naïve rodents has been shown to upregulate CB 1 receptor expression and/or functionality in different brain areas [18, 19, 51] . By contrast, the increased CB 1 receptor expression and coupling to G i/o proteins observed in the PFC of rats exposed to depression models is normalized by chronic ADs [13, 14] . Collectively, these results indicate that the consequences of antidepressant medications at the CB 1 receptor signaling level in the rodent brain depend on the pre-existence of a "depressive-like" state. In this study, the absence of modifications regarding CB 1 receptor coupling to Gα o proteins in AD-treated MD cases is in marked contrast with our findings in AD-free suicides (present report and Hungund et al. [26] ) and resembles the normalization of CB 1 receptor function in rodent models of depression following chronic AD treatment [13, 14] . Although caution is needed when evaluating these results, as only acute AD intake can be asserted from the positive blood testing at the time of death, our findings support the hypothesis that antidepressant medications modulate the activity of endocannabinoid system in the human brain.
Previous work has suggested that different biological and experimental parameters may modulate the expression and functionality of CB 1 receptors and other neurotransmitter receptor proteins, in postmortem human brain [52, 53] . The possible confounding effect of these variables in our results was avoided by matching the brain samples included in each experimental procedure in terms of age, sex and PM. A second limitation of the present study might be the fact that different cohorts of MD and matched controls were included in the four different assays carried out in order to address CB 1 receptor expression and functionality. Nevertheless, the possibility that this fact is behaving as a confounding factor seems unlikely for several reasons. First, seven out of a total number of twelve MD cases were common between all the experimental procedures, and always compared to matched controls. Consistently, the different MD and cohorts were similar in terms of age and PM. Finally, the observed increase of CB 1 receptor coupling to G i/o protein in the AD-free depressed suicides included in [ 35 
S]GTPγS
binding experiments is consistent with the enhanced coupling to Gα o subunits detected in immunoprecipitation assays, and so are the lack of modifications in CB 1 receptor expression and agonist-inhibition of adenylyl cyclase activity.
In summary, the present data suggest that enhanced CB 1 receptor signaling in the brain of depressed suicides involves augmented coupling to Gα o , and not to Gα i/z protein subunits, providing additional insights into the participation of dysregulated endocannabinoid signaling in the pathophysiology of MD. In addition, this study provides the first evidence that antidepressant medications may modulate endocannabinoid neurotransmission in the brain of depressed subjects. Although additional research is necessary in order to unveil the biological significance of upregulated CB 1 receptor function in MD, the present findings strengthen the idea that targeting brain endocannabinoid system could be a useful strategy for the clinical management of this devastating disorder.
